Trending...
- Naperville Police Host College Safety Webinar for Students and Parents on July 31
- AF 5.0: Why AF5.0 Is Becoming a Core Platform for Quantitative Education
- Open Appeal: Renew Indian Passports by Citizenship, Not Immigration Status
CHICAGO, June 22, 2025 ~ A new dual agonist, CagriSema, has shown promising results in improving weight loss for patients with and without type 2 diabetes who have overweight or obesity. The findings were presented at the 85th Scientific Sessions of the American Diabetes Association® (ADA) in Chicago and simultaneously published in the New England Journal of Medicine.
According to recent studies, nearly 90% of adults in the United States who have diabetes also have overweight or obesity. This highlights the strong connection between excess weight and the development or progression of type 2 diabetes. While there have been advancements in treatment options for obesity and type 2 diabetes with glucagon-like peptide-1 (GLP-1) receptor agonists, there is still a need for therapies that can address both weight and glucose management simultaneously.
CagriSema, a dual agonist that targets both appetite control and glucose regulation, aims to fill this gap. The drug is a once-weekly combination of semaglutide and cagrilintide, two weight-loss medications.
More on illi News
The effectiveness and safety of CagriSema were evaluated in two phase 3 studies known as REDEFINE 1 and REDEFINE 2. REDEFINE 1 included 3,400 adults without diabetes but with at least one weight-related health condition such as high blood pressure or heart disease. Participants were randomly assigned to receive CagriSema, semaglutide, cagrilintide, or placebo. On the other hand, REDEFINE 2 enrolled 1,200 adults with type 2 diabetes who received either CagriSema or placebo.
Both studies met their goals by demonstrating significant weight loss with once-weekly CagriSema compared to placebo. In REDEFINE 1, participants lost an average of 20.4% of their body weight at week 68 with CagriSema compared to only 3% with placebo. When considering full treatment adherence, weight loss with CagriSema increased to 22.7%, and 40.4% of participants achieved at least 25% weight loss. Similarly, in REDEFINE 2, participants lost an average of 13.7% of their body weight at week 68 with CagriSema compared to only 3.4% with placebo. When accounting for all study participants who adhered to treatment, weight loss with CagriSema rose to 15.7%, while only 3.1% was seen in the placebo group.
More on illi News
The safety profile of CagriSema was consistent with other GLP-1 receptor agonists, with mild-to-moderate gastrointestinal issues being the most common side effects.
Professor Melanie Davies from the University of Leicester commented on the findings, stating that they represent a significant step forward in expanding treatment options for people living with obesity and type 2 diabetes. She emphasized the importance of developing therapies that not only promote meaningful weight loss but also improve glucose control, giving patients more tools to manage their health effectively.
The researchers involved in this study note that it is part of a larger REDEFINE program that aims to evaluate the effectiveness of CagriSema across different populations and inform future regulatory submissions.
The findings were presented by Professor Davies and Dr. Timothy Garvey at a symposium during the ADA's Scientific Sessions on June 22nd at 8:00 a.m CT. The presentation focused on the efficacy and safety of CagriSema in adults with overweight or obesity based on data from REDEFINE 1 and REDEFINE 2 clinical trials.
According to recent studies, nearly 90% of adults in the United States who have diabetes also have overweight or obesity. This highlights the strong connection between excess weight and the development or progression of type 2 diabetes. While there have been advancements in treatment options for obesity and type 2 diabetes with glucagon-like peptide-1 (GLP-1) receptor agonists, there is still a need for therapies that can address both weight and glucose management simultaneously.
CagriSema, a dual agonist that targets both appetite control and glucose regulation, aims to fill this gap. The drug is a once-weekly combination of semaglutide and cagrilintide, two weight-loss medications.
More on illi News
- Bent Danholm To Be Featured On Global Podcast Network In Live Interview
- AdvoCast Expands Leadership in Strategic Comms with New Role Producing "Communication Breakdown" Podcast
- InventHelp Inventor Develops Wearable Tracking Device (CHK-2215)
- Naperville: Structure Fire in the 1000 Block of Frances Court
- Rocket.Chat assessed "Awardable" for Department of Defense work in the CDAO's Tradewinds Solutions Marketplace
The effectiveness and safety of CagriSema were evaluated in two phase 3 studies known as REDEFINE 1 and REDEFINE 2. REDEFINE 1 included 3,400 adults without diabetes but with at least one weight-related health condition such as high blood pressure or heart disease. Participants were randomly assigned to receive CagriSema, semaglutide, cagrilintide, or placebo. On the other hand, REDEFINE 2 enrolled 1,200 adults with type 2 diabetes who received either CagriSema or placebo.
Both studies met their goals by demonstrating significant weight loss with once-weekly CagriSema compared to placebo. In REDEFINE 1, participants lost an average of 20.4% of their body weight at week 68 with CagriSema compared to only 3% with placebo. When considering full treatment adherence, weight loss with CagriSema increased to 22.7%, and 40.4% of participants achieved at least 25% weight loss. Similarly, in REDEFINE 2, participants lost an average of 13.7% of their body weight at week 68 with CagriSema compared to only 3.4% with placebo. When accounting for all study participants who adhered to treatment, weight loss with CagriSema rose to 15.7%, while only 3.1% was seen in the placebo group.
More on illi News
- Suburban Orthopaedics Expands Foot and Ankle Team with Fellowship-Trained Surgeon Shoueb Malik, DPM
- Rising Home Values Aren't Preventing Foreclosures
- Success for Global Communications Leader IQSTEL, Inc. Growing From $13 Million Revenue in 2018 to Nearly $300 Million Last Year
- Designer Creates 100 Free Posters for Black Business Month
- Artbound: "The Cheech" Awarded Two 2025 LA Area EMMY Awards — Honored in ARTS & MUSIC COMPOSITION
The safety profile of CagriSema was consistent with other GLP-1 receptor agonists, with mild-to-moderate gastrointestinal issues being the most common side effects.
Professor Melanie Davies from the University of Leicester commented on the findings, stating that they represent a significant step forward in expanding treatment options for people living with obesity and type 2 diabetes. She emphasized the importance of developing therapies that not only promote meaningful weight loss but also improve glucose control, giving patients more tools to manage their health effectively.
The researchers involved in this study note that it is part of a larger REDEFINE program that aims to evaluate the effectiveness of CagriSema across different populations and inform future regulatory submissions.
The findings were presented by Professor Davies and Dr. Timothy Garvey at a symposium during the ADA's Scientific Sessions on June 22nd at 8:00 a.m CT. The presentation focused on the efficacy and safety of CagriSema in adults with overweight or obesity based on data from REDEFINE 1 and REDEFINE 2 clinical trials.
Filed Under: Business
0 Comments
Latest on illi News
- Private Autopsies Provide Families in Colorado with Answers and Closure
- Vijay Tirathrai named Managing Director in Dubai, UAE
- How smart women use BAY Miner cloud mining to easily earn Bitcoin every day
- Qualis LLC Appoints Jeremy Mallicoat as Chief Financial Officer to Advance Growth and Acquisition Strategy
- Bynn Intelligence Reinvents Document Fraud Detection with Groundbreaking Acquisition and Revolutionary AI Model
- Mentor Agile Says WIOA‑Funded Seats Still Available for Summer Product‑Owner
- 2A Commerce Launches Firearms eCommerce Platform
- GOAT SKIN® Launches the Campaign Tee: A Sovereign Statement in Luxury Apparel
- Midwest Pond Features & Landscape Says "We're Ready for Repairs"
- Brianne Zitko Named Winner of 2025 Great Companies International Women Entrepreneur Award
- 4Closure Rescue Expands Foreclosure Support Services to Underserved Communities Across the U.S
- Premier Protein® and Milk Bar® Launch New "Power Hour" Protein Menu
- Exposing Psychiatric Abuse, CCHR Has Pushed for Global Human Rights Protections
- Spur Chicago Builds Momentum Through Summer Field Collaborations
- RDG Mining launches 1-day XRP、BTC mining contract, XRP short-term investment users surge 500%
- Donna Cardellino and Paul Lafrance Sign Exclusive Deal for Worldwide Expansion into Commercial and Luxury Real Estate Design Projects
- New Book "Three Permissions" Redefines Self-Leadership for a Burnout-Weary Culture
- Opening a new era of USDC smart cloud mining: CJB Crypto makes digital dollar earnings within reach
- The Evolution of the BDCV Platform: Empowering Mental Health & Wellness
- DFS Fullcolor Printing by Inkdnylon | Nationwide Print Partner